

# **Burjeel Holdings PLC**

## **INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NINE MONTHS PERIOD ENDED 30 SEPTEMBER 2024 (UNAUDITED)**



Ernst & Young - Middle East  
(ADGM Branch)  
P.O. Box 136  
24th Floor, Office 2449, Sila Tower  
Abu Dhabi Global Market Square  
Al Maryah Island  
Abu Dhabi, United Arab Emirates

Tel: +971 2 417 4400  
+971 2 627 7522  
Fax: +971 2 627 3383  
abudhabi@ae.ey.com  
ey.com  
Registration No. 000001136

## **REPORT ON REVIEW OF INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TO THE DIRECTORS OF**

### **BURJEEL HOLDINGS PLC**

#### *Introduction*

We have reviewed the accompanying interim condensed consolidated financial statements of Burjeel Holdings PLC (the “Company”) and its subsidiaries (together referred to as the “Group”) as at 30 September 2024, comprising of the interim condensed consolidated statement of financial position as at 30 September 2024, and the related interim condensed consolidated statement of comprehensive income for three-months and nine-months periods then ended, the related interim condensed consolidated statements of changes in equity and cash flows for the nine-months period then ended and explanatory notes. Management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard 34 *Interim Financial Reporting* (“IAS 34”). Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

#### *Scope of review*

We conducted our review in accordance with International Standard on Review Engagements 2410, “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

#### *Conclusion*

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects in accordance with IAS 34.

For Ernst & Young Middle East (ADGM Branch)

Anthony O' Sullivan

05 November 2024  
Abu Dhabi, United Arab Emirates

# Burjeel Holdings PLC

## INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the three and nine month periods ended 30 September 2024 (unaudited)

	Notes	Three months ended 30 September		Nine months ended 30 September	
		2024	2023	2024	2023
		AED	AED	AED	AED
Revenue	4	<b>1,318,566,657</b>	1,155,409,696	<b>3,705,150,156</b>	3,317,239,551
Doctors' and other employees' salaries and emoluments		<b>(562,910,815)</b>	(491,622,456)	<b>(1,622,229,657)</b>	(1,444,865,628)
Inventories consumed		<b>(335,924,738)</b>	(289,589,029)	<b>(940,691,772)</b>	(806,584,044)
Depreciation on property and equipment	6	<b>(55,565,408)</b>	(57,974,497)	<b>(164,214,671)</b>	(174,555,560)
Amortisation of intangible assets		<b>(2,056,966)</b>	(933,207)	<b>(4,710,302)</b>	(2,662,103)
Depreciation on right-of-use assets		<b>(30,120,824)</b>	(30,785,860)	<b>(89,184,865)</b>	(84,172,750)
Provision for expected credit losses	10	<b>(28,622,348)</b>	(20,274,990)	<b>(74,522,798)</b>	(55,923,790)
Other expenses	5	<b>(122,367,040)</b>	(97,375,301)	<b>(369,665,656)</b>	(299,682,831)
<b>OPERATING PROFIT FOR THE PERIOD</b>		<b>180,998,518</b>	166,854,356	<b>439,930,435</b>	448,792,845
Finance costs		<b>(35,192,918)</b>	(33,569,890)	<b>(104,269,535)</b>	(104,130,406)
Change in fair value of financial assets carried at fair value through profit and loss		-	-	<b>(9,970,454)</b>	-
Share of profit from associates		<b>4,739,181</b>	3,774,924	<b>11,855,599</b>	17,110,885
<b>PROFIT BEFORE TAX FOR THE PERIOD</b>		<b>150,544,781</b>	137,059,390	<b>337,546,045</b>	361,773,324
Income tax	15	<b>(13,195,041)</b>	-	<b>(31,318,591)</b>	-
<b>PROFIT FOR THE PERIOD</b>		<b>137,349,740</b>	137,059,390	<b>306,227,454</b>	361,773,324
Other comprehensive income		-	-	-	-
<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>		<b>137,349,740</b>	137,059,390	<b>306,227,454</b>	361,773,324
<b>Profit for the period and total comprehensive income for the period attributable to:</b>					
Equity holders of the Parent Company		<b>130,526,838</b>	128,671,802	<b>294,111,486</b>	342,356,432
Non-controlling interests		<b>6,822,902</b>	8,387,588	<b>12,115,968</b>	19,416,892
		<b>137,349,740</b>	137,059,390	<b>306,227,454</b>	361,773,324
Earnings per share attributable to the equity holders of the Parent Company: - basic and diluted earnings per share (AED)	16	<b>0.03</b>	0.02	<b>0.06</b>	0.07


The accompanying notes 1 to 18 form an integral part of these interim condensed consolidated financial statements.


# Burjeel Holdings PLC


## INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 September 2024

	Notes	30 September 2024 AED (Unaudited)	31 December 2023 AED (Audited)
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property and equipment	6	1,888,484,688	1,914,555,641
Intangible assets		17,024,403	18,873,594
Right-of-use assets		947,621,690	1,010,791,935
Capital work in progress		59,143,609	39,916,220
Investment in associates		25,719,274	28,663,675
Deferred tax	15	6,248,998	-
Term deposits		<u>2,552,500</u>	<u>2,552,500</u>
		<b><u>2,946,795,162</u></b>	<b><u>3,015,353,565</u></b>
<b>Current assets</b>			
Inventories		261,161,218	261,272,228
Accounts receivable and prepayments	10	2,128,204,209	1,634,119,073
Amounts due from related parties	8	21,004,680	23,793,148
Financial asset carried at fair value through profit and loss	12	-	36,862,062
Bank balances and cash	7	<u>137,905,199</u>	<u>170,004,976</u>
		<b><u>2,548,275,306</u></b>	<b><u>2,126,051,487</u></b>
<b>TOTAL ASSETS</b>		<b><u>5,495,070,468</u></b>	<b><u>5,141,405,052</u></b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Share capital		520,513,417	520,513,417
Share premium		366,854,049	366,854,049
Other reserve		3,039,504	3,039,504
Shareholder's contribution		3,553,665	3,553,665
Retained earnings		<u>844,672,013</u>	<u>615,624,704</u>
<b>Equity attributable to equity holders of the parent</b>		<b>1,738,632,648</b>	<b>1,509,585,339</b>
Non-controlling interests		<u>49,587,561</u>	<u>47,471,593</u>
<b>Total equity</b>		<b><u>1,788,220,209</u></b>	<b><u>1,557,056,932</u></b>
<b>Non-current liabilities</b>			
Interest bearing loans and borrowings	9	821,964,987	782,086,391
Lease liabilities		1,009,982,865	1,062,444,262
Employees' end of service benefits		170,010,040	151,117,100
Derivative financial instrument	11	-	30,396,005
		<u>2,001,957,892</u>	<u>2,026,043,758</u>
<b>Current liabilities</b>			
Accounts payable and accruals		1,175,765,776	1,029,363,696
Lease liabilities		112,974,386	107,362,123
Interest bearing loans and borrowings	9	325,844,354	381,911,515
Income tax payable		37,656,343	-
Amounts due to related parties	8	<u>52,651,508</u>	<u>39,667,028</u>
		<b><u>1,704,892,367</u></b>	<b><u>1,558,304,362</u></b>
<b>Total liabilities</b>		<b><u>3,706,850,259</u></b>	<b><u>3,584,348,120</u></b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b><u>5,495,070,468</u></b>	<b><u>5,141,405,052</u></b>

  
Mr. John Sunil  
Chief Executive Officer

  
Mr. Safer Ahmed Ullatt  
Chief Operating Officer

  
Mr. Muhammed Shihabuddin  
Chief Financial Officer

The accompanying notes 1 to 18 form an integral part of these interim condensed consolidated financial statements.

# Burjeel Holdings PLC

## INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the nine months period ended 30 September 2024 (unaudited)

	Attributable to the equity holders of Parent						Non - controlling interest AED	Total equity AED
	Share capital AED	Share premium AED	Other reserve AED	Shareholder's contribution AED	Retained earnings AED	Total AED		
As at 1 January 2023 (audited)	520,513,417	366,854,049	3,039,504	3,553,665	194,686,535	1,088,647,170	29,199,928	1,117,847,098
Profit for the period (unaudited)	-	-	-	-	<u>342,356,432</u>	<u>342,356,432</u>	<u>19,416,892</u>	<u>361,773,324</u>
Total comprehensive income for the period (unaudited)	-	-	-	-	342,356,432	342,356,432	19,416,892	361,773,324
Dividend paid to non-controlling interest (unaudited) (note 17)	-	-	-	-	-	-	(6,000,000)	(6,000,000)
Dividend paid (unaudited) (note 17)	-	-	-	-	<u>(95,253,955)</u>	<u>(95,253,955)</u>	-	<u>(95,253,955)</u>
Balance at 30 September 2023 (unaudited)	<u>520,513,417</u>	<u>366,854,049</u>	<u>3,039,504</u>	<u>3,553,665</u>	<u>441,789,012</u>	<u>1,335,749,647</u>	<u>42,616,820</u>	<u>1,378,366,467</u>
As at 1 January 2024 (audited)	520,513,417	366,854,049	3,039,504	3,553,665	615,624,704	1,509,585,339	47,471,593	1,557,056,932
Profit for the period (unaudited)	-	-	-	-	<u>294,111,486</u>	<u>294,111,486</u>	<u>12,115,968</u>	<u>306,227,454</u>
Total comprehensive income for the period (unaudited)	-	-	-	-	294,111,486	294,111,486	12,115,968	306,227,454
Dividend paid to non-controlling interest (unaudited) (note 17)	-	-	-	-	-	-	(10,000,000)	(10,000,000)
Dividend paid (unaudited) (note 17)	-	-	-	-	<u>(65,064,177)</u>	<u>(65,064,177)</u>	-	<u>(65,064,177)</u>
Balance at 30 September 2024 (unaudited)	<u>520,513,417</u>	<u>366,854,049</u>	<u>3,039,504</u>	<u>3,553,665</u>	<u>844,672,013</u>	<u>1,738,632,648</u>	<u>49,587,561</u>	<u>1,788,220,209</u>

The accompanying notes 1 to 18 form an integral part of these interim condensed consolidated financial statements.

# Burjeel Holdings PLC

## INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the nine months period ended 30 September 2024 (unaudited)

	Notes	<i>Nine-month ended 30 September</i>	
		2024	2023
		<i>AED</i> <i>(Unaudited)</i>	<i>AED</i> <i>(Unaudited)</i>
<b>OPERATING ACTIVITIES</b>			
Profit before tax for the period		<b>337,546,045</b>	361,773,324
Adjustments for:			
Depreciation on property and equipment	6	<b>164,214,671</b>	174,555,560
Amortisation of intangible assets		<b>4,710,302</b>	2,662,103
Depreciation on right-of-use assets		<b>89,184,865</b>	84,172,750
Provision for expected credit losses	10	<b>74,522,798</b>	55,923,790
Changes in fair value of financial asset carried at fair value through profit and loss		<b>9,970,454</b>	-
Share of profit from investment in associates		<b>(11,855,599)</b>	(17,110,885)
Provision for employees' end of service benefits		<b>36,214,855</b>	36,314,861
Lease adjustment		<b>46,362</b>	(6,718,765)
Gain on disposal of property and equipment	6	<b>(325,280)</b>	-
Change in fair value of derivative financial instrument	11	<b>(12,075,467)</b>	(11,535,274)
Finance costs		<b>104,269,535</b>	104,130,406
		<b>796,423,541</b>	784,167,870
Working capital adjustments:			
Inventories		<b>111,010</b>	(355,650)
Accounts receivable and prepayments		<b>(569,997,934)</b>	(423,759,894)
Amounts due from related parties		<b>2,788,468</b>	3,731,188
Accounts payable and accruals		<b>146,402,080</b>	64,692,013
Amounts due to related parties		<b>12,984,480</b>	(5,069,365)
Cash generated from operations		<b>388,711,645</b>	423,406,162
Employees' end of service benefits paid		<b>(17,321,915)</b>	(15,489,078)
Finance costs paid		<b>(63,575,821)</b>	(64,896,049)
Net cash flows from operating activities		<b>307,813,909</b>	343,021,035
<b>INVESTING ACTIVITIES</b>			
Purchase of property and equipment	6	<b>(125,462,573)</b>	(92,095,295)
Additions to intangible assets		<b>(2,824,778)</b>	(4,856,090)
Additions to capital work in progress		<b>(32,512,807)</b>	(6,192,423)
Proceeds from disposal of property and equipment	6	<b>893,220</b>	381,304
Proceeds from sale of financial asset carried at fair value through profit or loss		<b>26,884,635</b>	-
Dividend income received from associates, net of investment		<b>14,800,000</b>	12,600,000
Net cash flows used in investing activities		<b>(118,222,303)</b>	(90,162,504)
<b>FINANCING ACTIVITIES</b>			
Payment of lease liabilities		<b>(112,118,103)</b>	(132,833,610)
Net movement in margin account		-	(601,629)
Dividend paid	17	<b>(65,064,177)</b>	(95,253,955)
Dividend paid to non-controlling interest	17	<b>(10,000,000)</b>	(6,000,000)
Settlement of derivative financial instrument	11	<b>(18,320,538)</b>	-
Proceeds from interest bearing loans and borrowings	9	<b>390,790,927</b>	1,583,696
Repayment of interest bearing loans and borrowings	9	<b>(406,979,492)</b>	(76,116,177)
Net cash flows used in financing activities		<b>(221,691,383)</b>	(309,221,675)
<b>NET DECREASE IN CASH AND CASH EQUIVALENTS</b>		<b>(32,099,777)</b>	(56,363,144)
Cash and cash equivalents at 1 January		<b>166,177,248</b>	146,736,382
<b>CASH AND CASH EQUIVALENTS AT 30 SEPTEMBER</b>	7	<b>134,077,471</b>	90,373,238

The accompanying notes 1 to 18 form an integral part of these interim condensed consolidated financial statements.

# Burjeel Holdings PLC

## NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 September 2024 (Unaudited)

### 1 ACTIVITIES

Burjeel Holdings PLC (the “Company” or the “Parent”) is registered in Abu Dhabi Global Market (ADGM) under license number 000003466 as a Public Company Limited by Shares. The Company was incorporated on 7 January 2020 (the “inception date”). The registered address of the Company is 402-DO2, 15th Floor, Al Sarab Tower, Abu Dhabi Global Market Square, Maryah Island, Abu Dhabi, United Arab Emirates. The Company and its subsidiaries are collectively referred to as the Group (the “Group”).

The principal activity of the Company is to act as a holding company (Proprietary Investment Company) for the entities within the Group. The principal activities of the subsidiaries are to provide multi-speciality hospitals, medical, surgical and dental services and sale of pharmaceutical goods and medical equipment.

The shareholding of the Company is as follows:

• VPS Healthcare Holdings PVT. Ltd	70.0%
• Quant Lase Lab LLC	14.4%
• SYA Holdings PVT. Ltd.	5.0%
• Publicly traded	10.6%

The interim condensed consolidated financial statements were approved by the Board of Directors and authorised for issue on 05 November 2024.

### 2 BASIS OF PREPARATION

#### 2.1 Statement of compliance

The interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard (“IAS 34”), Interim Financial Reporting.

The interim condensed consolidated financial statements do not include all information and disclosures required in the annual consolidated financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”), and should be read in conjunction with the Group’s annual consolidated financial statements as at 31 December 2023. In addition, results for the nine months period ended 30 September 2024 are not necessarily indicative of the results for the year ending 31 December 2024.

These interim condensed consolidated financial statements have been prepared on the historical cost basis, except for derivative financial instrument and financial asset carried at fair value through profit and loss which are stated at fair value.

During the period, the Group has reclassified certain comparative amounts to conform the presentation as in the current year.

The interim condensed consolidated financial statements are presented in United Arab Emirates Dirhams (“AED”), which is the functional currency of the Company and the presentation currency of the Group.

#### 2.2 Basis of consolidation

The interim condensed consolidated financial statements comprise the interim financial statements of the Company and its subsidiaries. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee).
- Exposure, or rights, to variable returns from its involvement with the investee.
- The ability to use its power over the investee to affect its returns.

**2 BASIS OF PREPARATION** continued

**2.2 Basis of consolidation** continued

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee.
- Rights arising from other contractual arrangements.
- The Group's voting rights and potential voting rights.

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the interim condensed consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of Other Comprehensive Income (OCI) are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

If the Group loses control over a subsidiary, it:

- Derecognises the assets (including goodwill) and liabilities of the subsidiary;
- Derecognises the carrying amount of any non-controlling interest;
- Derecognises the cumulative translation differences, recorded in equity;
- Recognises the fair value of the consideration received;
- Recognises the fair value of any investment retained;
- Recognises any surplus or deficit in profit or loss; and
- Reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss or retained earnings, as appropriate.

The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under IFRS 9, when applicable, or the cost on initial recognition of an investment in an associate or a joint venture.

**3 MATERIAL ACCOUNTING POLICY INFORMATION**

**3.1 New standards, interpretations and amendments adopted by the Group**

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2023, except for the adoption of new standards effective as of 1 January 2024. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Several amendments apply for the first time in 2024, but do not have an impact on the interim condensed consolidated financial statements of the Group.

- Supplier Finance Arrangements – Amendments to IAS 7 and IFRS 7.
- Amendments to IFRS 16: Lease Liability in a Sale and Leaseback.
- Amendments to IAS 1: Classification of liabilities as Current or Non-current.

The amendments had no impact on the Group's interim condensed consolidated financial statements.



NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
30 September 2024 (Unaudited)

**3 MATERIAL ACCOUNTING POLICY INFORMATION** continued

**3.2 Significant accounting estimates and judgements**

The preparation of the interim condensed consolidated financial statements in conformity with the International Financial Reporting Standards requires management to make judgment, estimates and assumptions that affect the application of accounting policies and reported amounts of financial assets and liabilities and the disclosure of contingent liabilities. These judgments, estimates and assumptions also affect the revenue, expenses and provisions as well as fair value changes. Actual results may differ from these estimates.

These judgments, estimates and assumptions may affect the reported amounts in subsequent financial years. Estimates and judgments are currently evaluated and are based on historical experience and other factors.

In preparing these interim condensed consolidated financial statements, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty are the same as those applied to the annual consolidated financial statements as at and for the year ended 31 December 2023.

**4 REVENUE**

**4.1 Types of revenue**

	<i>Three months ended 30 September</i>		<i>Nine months ended 30 September</i>	
	<i>2024 AED (Unaudited)</i>	<i>2023 AED (Unaudited)</i>	<i>2024 AED (Unaudited)</i>	<i>2023 AED (Unaudited)</i>
Clinic revenue	<b>1,271,294,154</b>	1,117,287,047	<b>3,574,963,789</b>	3,201,556,361
Pharmacy sales	<b>15,475,179</b>	13,159,201	<b>46,044,810</b>	44,117,927
Other operating income	<b>30,011,582</b>	23,623,291	<b>79,843,796</b>	66,688,621
Revenue from contracts with customers	<b>1,316,780,915</b>	1,154,069,539	<b>3,700,852,395</b>	3,312,362,909
Rental income	<b>1,785,742</b>	1,340,157	<b>4,297,761</b>	4,876,642
	<b><u>1,318,566,657</u></b>	<u>1,155,409,696</u>	<b><u>3,705,150,156</u></b>	<u>3,317,239,551</u>

**4.2 Revenue from contracts with customers by timing of recognition**

Out patient – services rendered at point in time	<b>829,231,860</b>	726,308,857	<b>2,305,496,271</b>	2,065,181,319
In patient – services rendered over time	<b>442,062,294</b>	390,978,190	<b>1,269,467,518</b>	1,136,375,042
Pharmacy – services rendered at point in time	<b>15,475,179</b>	13,159,201	<b>46,044,810</b>	44,117,927
Other operating income – services rendered at point in time	<b>9,773,187</b>	2,620,779	<b>26,880,941</b>	8,375,738
Other operating income – services rendered over time	<b>20,238,395</b>	21,002,512	<b>52,962,855</b>	58,312,883
	<b><u>1,316,780,915</u></b>	<u>1,154,069,539</u>	<b><u>3,700,852,395</u></b>	<u>3,312,362,909</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
30 September 2024 (Unaudited)

4 REVENUE continued

4.3 Revenue from contracts with customers by geographical markets

	<i>Three months ended 30 September</i>		<i>Nine months ended 30 September</i>	
	<i>2024 AED (Unaudited)</i>	<i>2023 AED (Unaudited)</i>	<i>2024 AED (Unaudited)</i>	<i>2023 AED (Unaudited)</i>
United Arab Emirates	<b>1,258,759,534</b>	1,105,870,735	<b>3,545,161,526</b>	3,180,973,988
Sultanate of Oman	<b>56,251,809</b>	48,198,804	<b>152,286,954</b>	131,388,921
Kingdom of Saudi Arabia	<b>1,769,572</b>	-	<b>3,403,915</b>	-
	<b><u>1,316,780,915</u></b>	<u>1,154,069,539</u>	<b><u>3,700,852,395</u></b>	<u>3,312,362,909</u>

4.4 Revenue from contracts with customers by asset type

	<i>Three months ended 30 September</i>		<i>Nine months ended 30 September</i>	
	<i>2024 AED (Unaudited)</i>	<i>2023 AED (Unaudited)</i>	<i>2024 AED (Unaudited)</i>	<i>2023 AED (Unaudited)</i>
Hospitals	<b>1,176,625,486</b>	1,007,455,340	<b>3,302,513,342</b>	2,886,647,843
Medical centres	<b>94,668,668</b>	109,831,707	<b>272,450,447</b>	314,908,518
Pharmacies	<b>15,475,179</b>	13,159,201	<b>46,044,810</b>	44,117,927
Others	<b>30,011,582</b>	23,623,291	<b>79,843,796</b>	66,688,621
	<b><u>1,316,780,915</u></b>	<u>1,154,069,539</u>	<b><u>3,700,852,395</u></b>	<u>3,312,362,909</u>

**Performance obligations**

The performance obligation is satisfied based on the nature of medical services or upon delivery of the medical goods or supplies in case of pharmacy items. Certain contracts for the sale of pharmacy items provide customers with a right of return. However, the sales returns are negligible as compared to the gross revenue for the sale of pharmacy items. Based on the analysis of the historical data and experience, sales return is estimated to be less than 0.05% of the total sales made during a financial year. Considering that the sales returns of the Group are not significant, the Group has not recorded a refund liability and a right of return asset for anticipated sales returns as of the reporting dates.

In the Middle East, the normal business process associated with transactions with insurers includes a number of claims disallowed which is not paid by the insurer. These rejected claims could be for various technical or medical reasons. Accordingly, the healthcare entities within the Group expect an amount of consideration that is less than what was originally invoiced. These rejections constitute variable consideration under IFRS 15. Variable consideration is recognised as revenue to the extent that it is highly probable that a reversal of revenue will not occur. Under IFRS 15, these rejected claims are recognised as part of revenue (decreasing the revenue recognised).

*Rental income*

The rental income received from external parties during the year from the letting of excess or unused spaces in the hospitals and medical centres. Rental income is based on individual lease agreements with a committed lease term of 1 year or less. Therefore, these are categorised as short-term leases.

There are no unsatisfied performance obligations as of the reporting dates; therefore, there are no transaction prices that are required to be allocated over the remaining or unsatisfied performance obligations.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
30 September 2024 (Unaudited)

**5 OTHER EXPENSES**

	<i>Three months ended</i>		<i>Nine months ended</i>	
	<i>30 September</i>		<i>30 September</i>	
	<i>2024</i>	<i>2023</i>	<i>2024</i>	<i>2023</i>
	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Housekeeping and hospitality expenses	<b>21,761,547</b>	22,236,643	<b>64,018,307</b>	58,203,732
Advertisement and marketing expenses	<b>20,526,459</b>	15,902,703	<b>61,315,929</b>	37,208,968
Repair and maintenance costs	<b>21,160,578</b>	21,609,918	<b>58,275,131</b>	52,992,194
Utility charges	<b>12,924,708</b>	15,303,567	<b>38,655,991</b>	37,446,712
Director's remuneration* (note 8)	<b>4,561,449</b>	4,561,599	<b>40,705,085</b>	18,246,173
Legal and professional expenses	<b>7,505,560</b>	8,210,108	<b>24,757,188</b>	22,444,573
Transportation expenses	<b>6,452,913</b>	4,519,296	<b>17,101,369</b>	13,438,106
Security charges	<b>4,521,418</b>	3,967,387	<b>12,874,663</b>	11,679,971
Rent expenses	<b>3,258,923</b>	4,441,861	<b>10,284,028</b>	12,890,790
Bank charges	<b>1,920,707</b>	2,268,126	<b>6,656,131</b>	5,982,290
Printing and stationery expenses	<b>2,290,656</b>	2,107,515	<b>6,120,069</b>	5,873,669
Credit card commission expenses	<b>1,735,490</b>	1,054,010	<b>3,815,048</b>	3,289,962
(Gain) on profit rate swap	-	(13,161,255)	<b>(12,075,467)</b>	(11,535,274)
Miscellaneous and other expenses	<b>13,746,632</b>	4,353,823	<b>37,162,184</b>	31,520,965
	<b><u>122,367,040</u></b>	<u>97,375,301</u>	<b><u>369,665,656</u></b>	<u>299,682,831</u>

\* Includes bonus amounting to AED 27,020,738 (equivalent to 5% of the profit for the year ended 31 December 2023), approved by shareholders of the Company in the Annual General Meeting held on 5 April 2024.

**6 PROPERTY AND EQUIPMENT**

The movement in property and equipment pertains to additions of AED 125,462,573 for the nine months period ended 30 September 2024 (nine months period ended 30 September 2023: AED 92,095,295) which comprises of building and leasehold improvements of AED 26,211,923 (2023: AED 16,662,997), medical equipment of AED 57,823,413 (2023: AED 46,337,601), furniture and fixtures of AED 10,877,834 (2023: AED 8,376,725), computer and office equipment of AED 20,350,108 (2023: AED 14,885,259) and motor vehicles of AED 10,199,295 (2023: AED 5,832,713).

Further, during the nine months period ended 30 September 2024, transfers amounting to AED 13,249,085 from capital work in progress to property and equipment (nine months period ended 30 September 2023: Nil) which comprises of building and leasehold improvements of AED 10,346,442 (2023: Nil), medical equipment of AED 1,864,215 (2023: Nil), furniture and fixtures of AED 308,215 (2023: Nil), computer and office equipment of AED 213,656 (2023: Nil) and motor vehicles of AED 516,557 (2023: AED Nil).

During the nine months period ended 30 September 2024, motor vehicles having net book value of AED 526,595, furniture and fixtures having net book value of AED 41,345 and computers and office equipment having net book value of AED nil were disposed at AED 893,220 resulting in gain of AED 325,280 on disposal (nine months period ended 30 September 2023: Nil).

The depreciation charge for the three months and nine months period ended amounted to AED 55,565,408 and AED 164,214,671, respectively (three months and nine months period ended 30 September 2023: AED 57,974,497 and AED 174,555,560, respectively).

See note 13 for capital commitments.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
30 September 2024 (Unaudited)

**7 BANK BALANCES AND CASH**

	<i>30 September 2024 AED (Unaudited)</i>	<i>31 December 2023 AED (Audited)</i>
Cash in hand	5,485,682	3,394,146
<i>Bank balances:</i>		
Current account	128,421,096	162,612,409
Fixed deposits	170,693	170,693
Margin deposits	<u>3,827,728</u>	<u>3,827,728</u>
Bank balances and cash	<u>137,905,199</u>	<u>170,004,976</u>

For the purpose of the interim condensed consolidated statement of cash flows, cash and cash equivalents comprise the following at 30 September 2024 and 31 December 2023:

	<i>30 September 2024 AED (Unaudited)</i>	<i>31 December 2023 AED (Audited)</i>
Bank balances and cash	137,905,199	170,004,976
Less: margin deposits	<u>(3,827,728)</u>	<u>(3,827,728)</u>
Cash and cash equivalents	<u>134,077,471</u>	<u>166,177,248</u>

Margin deposits are cash guarantees paid to various banks. These deposits are not liquid and are not readily convertible to cash as they are subordinated to the respective facilities. Therefore, these deposits are excluded from cash and cash equivalents.

The expected credit loss on bank balances is estimated to be immaterial as the Group only deals with reputable banks with good ratings.

	<i>30 September 2024 AED (Unaudited)</i>	<i>30 September 2023 AED (Unaudited)</i>
<b>Significant non-cash transactions</b>		
Employees' end of service benefits transferred from a related party (note 8)	-	3,259,206
Leave salary transferred from a related party (note 8)	-	558,591
Property and equipment transferred from a related party (note 8)	-	140,924
Property and equipment transferred to a related party (note 8)	-	381,304
Transfer from prepayment to right-of-use assets	<b>1,390,000</b>	-

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
30 September 2024 (Unaudited)

## 8 RELATED PARTY TRANSACTIONS AND BALANCES

These represent transactions with related parties, i.e., shareholders and senior management of the Group, and entities controlled, jointly controlled or significantly influenced by such parties. Pricing policies and terms of all transactions are approved by the management of the Group.

Transactions with related parties included in the interim condensed consolidated statement of comprehensive income are as follows:

	<i>Three months ended</i>		<i>Nine months ended</i>	
	<i>30 September</i>		<i>30 September</i>	
	<i>2024</i>	<i>2023</i>	<i>2024</i>	<i>2023</i>
	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Revenue	<u>905,499</u>	<u>665,331</u>	<u>2,052,235</u>	<u>3,917,572</u>
Purchases	<u>6,965,581</u>	<u>5,389,330</u>	<u>19,123,733</u>	<u>16,175,441</u>
Doctors' and other employees' salaries and benefits	<u>566,384</u>	<u>482,762</u>	<u>1,668,895</u>	<u>1,786,793</u>
Directors' remuneration (note 5)	<u>4,561,449</u>	<u>4,561,599</u>	<u>40,705,085</u>	<u>18,246,173</u>
Hospitality expenses	<u>5,860,382</u>	<u>5,154,058</u>	<u>20,634,846</u>	<u>16,100,607</u>
Others	<u>2,195,518</u>	<u>2,147,610</u>	<u>8,010,363</u>	<u>9,882,145</u>
End of service benefits transferred from a related party (note 7)	<u>-</u>	<u>-</u>	<u>-</u>	<u>3,259,206</u>
Leave salary transferred from a related party (note 7)	<u>-</u>	<u>-</u>	<u>-</u>	<u>558,591</u>
Property and equipment transferred to a related party (note 7)	<u>-</u>	<u>381,304</u>	<u>-</u>	<u>381,304</u>
Property and equipment transferred from a related party (note 7)	<u>-</u>	<u>-</u>	<u>-</u>	<u>140,924</u>

### Compensation of key management personnel

The remuneration of the members of key management during the period was as follows:

	<i>Three months ended</i>		<i>Nine months ended</i>	
	<i>30 September</i>		<i>30 September</i>	
	<i>2024</i>	<i>2023</i>	<i>2024</i>	<i>2023</i>
	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>	<i>(Unaudited)</i>
Salaries, end of service and other benefits	<u>1,317,500</u>	<u>1,317,500</u>	<u>8,702,500</u>	<u>3,454,500</u>
Number of key management personnel	<u>2</u>	<u>2</u>	<u>2</u>	<u>2</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
30 September 2024 (Unaudited)

**8 RELATED PARTY TRANSACTIONS AND BALANCES** continued

	<i>30 September</i> <i>2024</i> <i>AED</i> <i>(Unaudited)</i>	<i>31 December</i> <i>2023</i> <i>AED</i> <i>(Audited)</i>
<b>Amounts due from related parties</b>		
<i>Entities under common control</i>		
VPS Healthcare LLC	<b>12,305,285</b>	12,562,710
Others	<b><u>8,699,395</u></b>	<u>11,230,438</u>
	<b><u>21,004,680</u></b>	<u>23,793,148</u>

Outstanding balances at the period end arise in the normal course of business and due to receipt and payment transactions. The Entities have not recorded any impairment of amounts due from related parties. This assessment is undertaken each reporting date through examining the financial position of the related party and the market in which the related party operates.

	<i>30 September</i> <i>2024</i> <i>AED</i> <i>(Unaudited)</i>	<i>31 December</i> <i>2023</i> <i>AED</i> <i>(Audited)</i>
<b>Amounts due to related parties</b>		
<i>Entities under common control</i>		
Others	<b><u>52,651,508</u></b>	<u>39,667,028</u>

As at 30 September 2024 and 31 December 2023, various group entities have provided corporate guarantees to the banks for loans and other facilities obtained by the subsidiaries and by the Company.

**9 INTEREST BEARING LOANS AND BORROWINGS**

	<i>30 September</i> <i>2024</i> <i>AED</i> <i>(Unaudited)</i>	<i>31 December</i> <i>2023</i> <i>AED</i> <i>(Audited)</i>
Term loans	<b>894,497,591</b>	906,465,959
Short-term loan	<b>247,000,000</b>	250,000,000
Vehicle loans	<b><u>6,311,750</u></b>	<u>7,531,947</u>
	<b><u>1,147,809,341</u></b>	<u>1,163,997,906</u>

Current and non-current portion of interest-bearing loans and borrowings can be analysed as follows:

	<i>30 September</i> <i>2024</i> <i>AED</i> <i>(Unaudited)</i>	<i>31 December</i> <i>2023</i> <i>AED</i> <i>(Audited)</i>
Non-current	<b>821,964,987</b>	782,086,391
Current	<b><u>325,844,354</u></b>	<u>381,911,515</u>
	<b><u>1,147,809,341</u></b>	<u>1,163,997,906</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
30 September 2024 (Unaudited)

**9 INTEREST BEARING LOANS AND BORROWINGS** continued

Movement in the interest bearing loans and borrowings during the period / year is as follows:

	<i>30 September 2024 AED (Unaudited)</i>	<i>31 December 2023 AED (Audited)</i>
At 1 January	<b>1,163,997,906</b>	1,260,792,098
Additions during the period / year	<b>390,790,927</b>	5,068,096
Repayments during the period / year	<b><u>(406,979,492)</u></b>	<u>(101,862,288)</u>
At the end of the period / year	<b><u>1,147,809,341</u></b>	<u>1,163,997,906</u>

During the period ended 30 September 2024, the Company entered into an agreement with a commercial bank in Abu Dhabi to repay the existing loans and acquire new investments ("Loan 1"). The facility was secured by irrevocable corporate guarantees of specific subsidiaries. The facility was further secured by pledge over collection accounts, mortgage over plant and equipment and assignment of insurance and credit card receivables of specific subsidiaries (except Burjeel Hospital LLC).

Further, during the period ended 30 September 2024, the Company entered into another loan agreement with a commercial bank in Abu Dhabi aggregating to AED 1,322 million ("Loan 2"), for the purpose of new permitted investments and to repay the existing loans. The facility is secured by guarantees from the subsidiaries of the Company. As at 30 September 2024, AED 209 million has been drawn from the total facility amount.

Loan 1 was settled during the period from the proceeds of Loan 2.

**Interest rates**

Interest rates on these loans and borrowings are at EIBOR plus a fixed margin. The range is as follows:

Commercial loans	- EIBOR + 1.65% to 3% (2023: EIBOR + 1.9% to 3%)
Vehicle loans	- 3% to 10% (2023: 3% to 10%)

**10 ACCOUNTS RECEIVABLE AND PREPAYMENTS**

	<i>30 September 2024 AED (Unaudited)</i>	<i>31 December 2023 AED (Audited)</i>
Trade receivables	<b>2,614,505,397</b>	2,187,419,636
Unbilled receivables	<b>121,813,557</b>	74,106,512
Less: provision for expected credit losses	<b><u>(861,194,559)</u></b>	<u>(786,671,761)</u>
	<b>1,875,124,395</b>	1,474,854,387
Advances and other receivables	<b>169,392,632</b>	102,363,731
Prepayments	<b>63,660,153</b>	40,887,443
Deposits	<b><u>20,027,029</u></b>	<u>16,013,512</u>
	<b><u>2,128,204,209</u></b>	<u>1,634,119,073</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
30 September 2024 (Unaudited)

**10 ACCOUNTS RECEIVABLE AND PREPAYMENTS** continued

Trade receivables and unbilled receivables include amounts due from insurance companies for goods sold or services performed in the ordinary course of business. Trade receivables are generally due for settlement within 90 days and therefore are all classified as current. Trade receivables and unbilled receivables are recognised initially at the amount of consideration that is unconditional. The Group holds the trade receivables and unbilled receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method.

Movement in the provision for expected credit losses is as follows:

	<b>30 September 2024 AED (Unaudited)</b>	<b>31 December 2023 AED (Audited)</b>
At 1 January	<b>786,671,761</b>	704,675,768
Charge for the year	<b>74,522,798</b>	84,113,351
Write off during the year	<b>-</b>	(2,117,358)
At 31 December	<b><u>861,194,559</u></b>	<u>786,671,761</u>

As at 31 December, the ageing analysis of unimpaired trade receivables is as follows:

	<i>Neither past due nor impaired</i>	<i>Past due but not impaired</i>				
		<i>&lt; 30 days</i>	<i>31 - 90 days</i>	<i>91 - 300 days</i>	<i>&gt; 300 days</i>	
<i>Total AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>	
<b>30 September 2024 (Unaudited)</b>	<b>1,875,124,395</b>	<b>1,045,855,139</b>	<b>202,872,271</b>	<b>274,901,777</b>	<b>308,561,076</b>	<b>42,934,132</b>
31 December 2023 (Audited)	1,474,854,387	846,519,283	165,080,152	178,992,425	240,756,544	43,505,983

Unimpaired receivables are expected, on the basis of past experience, to be fully recoverable. It is not the practice of the Group to obtain collateral over receivables and the receivables are, therefore, unsecured. Neither past due nor impaired are those receivables which are under review and approval process with the insurance companies. Credit risk is limited to the carrying values of financial assets in the consolidated statement of financial position.

**11 DERIVATIVE FINANCIAL INSTRUMENT**

The Group had entered into a profit rate swap agreement with Islamic bank in United Arab Emirates to manage its interest rate exposure. The changes in the fair value of the derivative amounting to AED 12,075,467 for the nine months period ended 30 September 2024 (30 September 2023: AED 11,535,274 (profit)) are included as a component of other expenses in the interim condensed consolidated statement of comprehensive income.

The fair value of the Group's derivative financial instrument as at 30 September 2024 and 31 December 2023 is as follows:

	<b>30 September 2024 AED (Unaudited)</b>	<b>31 December 2023 AED (Audited)</b>
Profit rate swap – non-current liabilities	<b><u>-</u></b>	<b><u>30,396,005</u></b>



**11 DERIVATIVE FINANCIAL INSTRUMENT** continued

Movement in the derivative financial instrument during the period / year is as follows:

	<b>30 September 2024 AED (Unaudited)</b>	<b>31 December 2023 AED (Audited)</b>
At 1 January	<b>30,396,005</b>	28,374,631
Changes in fair value	<b>(12,075,467)</b>	2,021,374
Settlement during the period / year	<b><u>(18,320,538)</u></b>	<u>-</u>
	<b><u>-</u></b>	<b><u>30,396,005</u></b>

As at 30 September 2024, the Group has settled interest rate swap which was used to limit exposure to interest rate increases related to a portion of the floating rate indebtedness. As at 30 September 2024, the aggregate notional principal amount of the outstanding interest rate swap contract amounts to AED Nil (31 December 2023: AED 754,049,451). The derivative financial instrument represented the recognition of a financial liability amounting to AED 30,396,005 as at 31 December 2023 relating to the fair value adjustment of the profit rate swap.

The fair value of the profit rate swap is estimated using quotes from external sources or the counterparty to the instruments. In valuing unquoted instruments, valuation techniques, including discounted cash flow models and option pricing models, are used as appropriate. The gain / loss on the interest rate swap is recognised in the interim condensed consolidated statement of comprehensive income for respective periods.

The levels of fair value inputs used to measure the investments are characterised in accordance with the fair value hierarchy established by IFRS 7. The management uses its judgment and consider factors specific to the investment in determining the significance of an input to a fair value measurement. The three levels of the fair value hierarchy and investments that fall into each of the levels are described below:

**Level 1:** Level 1 inputs are unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. The Group uses Level 1 inputs for investments in publicly traded unrestricted securities for which the Group does not have a controlling interest. The Group does not measure the fair value of the financial instruments using Level 1 inputs as of 31 December 2023.

**Level 2:**

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined by using valuation techniques. As level 2 investments include positions that are not traded in active markets and/or are subject to transfer restrictions, valuations may be adjusted to reflect illiquidity and/or non-transferability, which are generally based on available market information. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. The Group measures the fair value of financial instrument using this category.

**Level 3:**

Level 3 inputs are unobservable and cannot be corroborated by observable market data. The Group does not measure the fair value of the financial instruments using Level 3 inputs as of 31 December 2023.

Due to the uncertainty inherent in the valuation process, such estimates of fair value may differ significantly from the values that would have been used had a ready market for the securities existed, and the differences could be material. Additionally, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these instruments to be different than the valuations currently assigned.

During the period ended 30 September 2024 and year ended 31 December 2023, there were no transfers between Level 1 and Level 2 fair value measurements, and no transfers into and out of Level 3 fair value measurements.

## 12 FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability; or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Group.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the interim condensed consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1:* Quoted (unadjusted) prices in active markets for identical assets or liabilities;  
*Level 2:* Other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and  
*Level 3:* Techniques which use inputs which have a significant effect on the recorded fair value that are not based on observable market data.

There were no transfers between Level 1 and Level 2 fair value measurements during the period, and no transfers into or out of Level 3 fair value measurements during the period ended 30 September 2024.

For assets and liabilities that are recognised in the interim condensed consolidated financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

	<i>Fair value as at</i>		<i>Fair value hierarchy</i>	<i>Valuation techniques and key inputs</i>	<i>Significant unobservable input</i>	<i>Relationship of unobservable inputs to fair value</i>
	<i>30 September 2024</i>	<i>31 December 2023</i>				
	<i>AED</i>	<i>AED</i>				
<b><i>Financial assets</i></b>						
Quoted equity investments – investment in financial assets	-	36,862,062	Level 1	Quoted bid prices in an active market.	None	Not applicable
<b><i>Financial liabilities</i></b>						
Derivative financial instruments - Profit rate swaps measured at fair value (note 11)	-	30,396,005	Level 2	Significant observable inputs	None	Not applicable

The management assessed that the fair values of all other financial assets and financial liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

**13 CONTINGENCIES AND COMMITMENTS****Contingencies**

At 30 September 2024, the Group had contingent liabilities in respect of labour guarantees amounting to AED 18,948,992 (31 December 2023: AED 3,909,531) and performance guarantees amounting to AED 9,611,572 (31 December 2023: AED 11,584,099) arising in the ordinary course of business from which it is anticipated that no material liabilities will arise.

**Capital commitments**

Capital expenditure contracted but not yet incurred at the end of the period / year as follows:

	<i>30 September 2024 AED (Unaudited)</i>	<i>31 December 2023 AED (Audited)</i>
Software	<b>44,380,319</b>	47,279,099
Building improvements	<b>33,741,238</b>	31,050,934
Medical equipment	<b>6,326,699</b>	16,355,018
Others	<b><u>7,708,349</u></b>	<u>3,393,828</u>
	<b><u>92,156,605</u></b>	<u>98,078,879</u>

**14 SEASONALITY OF RESULTS**

No significant income of seasonal nature was recorded in the interim condensed consolidated statement of comprehensive income for the three months and nine months period ended 30 September 2024 and 30 September 2023.

**15 INCOME TAX**

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major component of income tax expense in the interim condensed consolidated statement of comprehensive income are:

**15.1 Amount recognised in the interim condensed consolidated statement of comprehensive income**

The major components of income tax expense for the period ended 30 September 2024:

	<i>Three months ended 30 September 2024 AED (Unaudited)</i>	<i>Nine months ended 30 September 2024 AED (Unaudited)</i>
Current income tax charge	<b>15,545,075</b>	<b>37,567,589</b>
Deferred income tax credit relating to origination and reversal of temporary differences	<b><u>(2,350,034)</u></b>	<b><u>(6,248,998)</u></b>
Income tax expense reported in the interim condensed consolidated statement of comprehensive income	<b><u>13,195,041</u></b>	<b><u>31,318,591</u></b>

# Burjeel Holdings PLC

## NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 September 2024 (Unaudited)

### 15 INCOME TAX continued

#### 15.2 Reconciliation of accounting income

	<i>Three months ended</i> <i>30 September</i> <i>2024</i> <i>AED</i> <i>(Unaudited)</i>	<i>Nine months ended</i> <i>30 September</i> <i>2024</i> <i>AED</i> <i>(Unaudited)</i>
Profit before tax	150,544,781	337,546,045
Add: (profit) loss related to foreign entities	(13,477,257)	2,496,900
Add: dividend income not considered above	<u>-</u>	<u>14,800,000</u>
Accounting profit before tax relating to UAE entities	137,067,524	354,842,945
At United Arab Emirates' statutory income tax rate of 9%	12,331,194	31,935,865
Add / less: effect of standard exemption	40,736	(44)
Add / less: income not subject to tax	241,672	(1,791,442)
Add: non-deductible expenses	-	-
Less: movement of carryforward loss	27,848	-
Add: tax related to foreign entities	<u>553,591</u>	<u>1,174,212</u>
Income tax expense reported in the interim condensed consolidated statement of comprehensive income	<u>13,195,041</u>	<u>31,318,591</u>
Effective tax rate	<u>9%</u>	<u>9%</u>

At 30 September 2024, there were no amounts recognised directly to equity or in other comprehensive income

### 16 BASIC AND DILUTED EARNINGS PER SHARE

Basic earnings per share are calculated by dividing the profit for the period attributed to the Equity holders of the Parent by the weighted average number of shares outstanding during the period.

Diluted earnings per share amounts are calculated by dividing the net profit for the period attributable to the Equity holders of the Parent by the weighted average number of ordinary shares outstanding during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

The information necessary to calculate basic and diluted earnings per share is as follows:

	<i>Three months ended</i> <i>30 September</i>		<i>Nine months ended</i> <i>30 September</i>	
	<i>2024</i> <i>AED</i> <i>(Unaudited)</i>	<i>2023</i> <i>AED</i> <i>(Unaudited)</i>	<i>2024</i> <i>AED</i> <i>(Unaudited)</i>	<i>2023</i> <i>AED</i> <i>(Unaudited)</i>
<b>Earnings:</b>				
Profit attributable to equity holders of the Parent (AED)	<u>130,526,838</u>	<u>128,671,802</u>	<u>294,111,486</u>	<u>342,356,432</u>
<b>Number of shares</b>				
Weighted-average number of ordinary shares for basic and diluted earnings per share	<u>5,205,134,170</u>	<u>5,205,134,170</u>	<u>5,205,134,170</u>	<u>5,205,134,170</u>
<b>Earnings per share</b>				
Basic and diluted earnings per share (AED)	<u>0.03</u>	<u>0.02</u>	<u>0.06</u>	<u>0.07</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
30 September 2024 (Unaudited)

**16 BASIC AND DILUTED EARNINGS PER SHARE** continued

During the period, there is no dilution in the weighted average number of shares.

There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorisation of these interim condensed consolidated financial statements.

**17 DIVIDEND**

	<i>Nine months ended 30 September</i>	
	<u>2024</u>	<u>2023</u>
	<i>AED</i>	<i>AED</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
<b>Dividends on ordinary shares declared and paid</b>		
Final dividend: AED 0.01 per share	<b>65,064,177</b>	-
Interim dividend: AED 0.01 per share	-	95,253,955

One of the Group's subsidiaries, Lifecare Hospital LLC, issued cash dividends during the nine months ended 30 September 2024 (nine months ended 30 September 2023: Nil). The amount paid / received within the Group was eliminated on consolidation and the amounts paid to non-controlling interests were AED 10,000,000 (nine months ended 30 September 2023: AED 6,000,000).

**18 SEGMENTAL REPORTING**

For management purposes, the Group is organised into business units or segments based on its products and services and has four reportable segments as follows:

- Hospitals;
- Medical Centre;
- Pharmacies; and
- Others

Hospital includes entities that provide inpatient, day-care services and outpatient services to patients to diagnosis the disease and offer medical and surgical treatment as part of in-patient services.

Medical Centre includes entities which offer only outpatient services to patients which includes medical consultation, lab and radiology diagnostic treatment (if required), will refer the patient to hospitals for Inpatient and day care services, if needed.

Pharmacies includes all the retail pharmacies which are outside the premises of the hospitals and medical centres. Pharmacies act as retail stores and selling pharmaceutical and cosmetic products.

Other represents business units that support the hospitals, medical centre and pharmacies to manage the supply chain, valet parking and claim submission etc.

No operating segments have been aggregated to form the above reportable operating segments.

The Chief Executive Officer of the Group is the Chief Operating Decision Maker (CODM) and monitors the operating results of the operating segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the interim condensed consolidated financial statements. Also, income taxes are managed on a Group basis and are not allocated to operating segments.

Segment performance is evaluated based on profit or loss including EBIT and EBITDA and is measured consistently with profit or loss in the interim condensed consolidated financial statements.

# Burjeel Holdings PLC

## NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 September 2024 (Unaudited)

### 18 SEGMENTAL REPORTING continued

As at and for the nine months period 30 September 2024:

	Hospitals centres AED	Medical centres AED	Pharmacies AED	Others AED	Total segments AED	Adjustments and eliminations AED	Consolidation AED
<b>Revenue</b>							
Out patient revenue	2,160,556,786	276,161,879	-	-	2,436,718,665	(131,222,394)	2,305,496,271
In patient revenue	<u>1,269,467,518</u>	-	-	-	<u>1,269,467,518</u>	-	<u>1,269,467,518</u>
Total clinical revenue	3,430,024,304	276,161,879	-	-	3,706,186,183	(131,222,394)	3,574,963,789
Pharmacy sales	-	-	46,403,622	-	46,403,622	(358,812)	46,044,810
Others	38,654,217	4,339,851	688,392	958,935,504	1,002,617,964	(922,774,168)	79,843,796
Rental income	<u>4,297,761</u>	-	-	-	<u>4,297,761</u>	-	<u>4,297,761</u>
<b>Total revenue</b>	<u>3,472,976,282</u>	<u>280,501,730</u>	<u>47,092,014</u>	<u>958,935,504</u>	<u>4,759,505,530</u>	<u>(1,054,355,374)</u>	<u>3,705,150,156</u>
<b>Revenue</b>							
External customers	3,340,435,288	276,790,298	46,733,202	41,191,368	3,705,150,156	-	3,705,150,156
Intersegment	<u>132,540,994</u>	<u>3,711,432</u>	<u>358,812</u>	<u>917,744,136</u>	<u>1,054,355,374</u>	<u>(1,054,355,374)</u>	-
<b>Total revenue</b>	<u>3,472,976,282</u>	<u>280,501,730</u>	<u>47,092,014</u>	<u>958,935,504</u>	<u>4,759,505,530</u>	<u>(1,054,355,374)</u>	<u>3,705,150,156</u>
<b>Segment profit before tax</b>	427,104,196	35,356,948	2,548,225	(127,463,324)	337,546,045	-	337,546,045
Finance costs	<u>90,771,914</u>	<u>1,193,215</u>	-	<u>12,304,406</u>	<u>104,269,535</u>	-	<u>104,269,535</u>
<b>Profit before interest, taxation (EBIT)</b>	517,876,110	36,550,163	2,548,225	(115,158,918)	441,815,580	-	441,815,580
Depreciation and amortisation	<u>234,095,351</u>	<u>20,989,243</u>	<u>513,291</u>	<u>2,511,953</u>	<u>258,109,838</u>	-	<u>258,109,838</u>
<b>Profit before interest, taxation, depreciation, amortisation (EBITDA)</b>	<u>751,971,461</u>	<u>57,539,406</u>	<u>3,061,516</u>	<u>(112,646,965)</u>	<u>699,925,418</u>	-	<u>699,925,418</u>
<b>Total assets as at 30 September 2024</b>	<u>8,507,511,817</u>	<u>647,817,617</u>	<u>179,293,477</u>	<u>2,696,329,473</u>	<u>12,030,952,384</u>	<u>(6,535,881,916)</u>	<u>5,495,070,468</u>
<b>Total liabilities as at 30 September 2024</b>	<u>7,090,201,152</u>	<u>610,073,398</u>	<u>175,780,295</u>	<u>2,429,187,531</u>	<u>10,305,242,376</u>	<u>(6,598,392,117)</u>	<u>3,706,850,259</u>
Other disclosures:							
Additions to property and equipment	108,581,392	14,592,682	789,302	1,499,197	125,462,573	-	125,462,573
Additions to intangibles	2,274,275	524,003	-	26,500	2,824,778	-	2,824,778
Additions to capital work in progress	<u>17,087,912</u>	<u>2,035,176</u>	-	<u>13,389,719</u>	<u>32,512,807</u>	-	<u>32,512,807</u>

# Burjeel Holdings PLC

## NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 September 2024 (Unaudited)

### 18 SEGMENTAL REPORTING continued

For the nine months period 30 September 2023 and as at 31 December 2023:

	<i>Hospitals AED</i>	<i>Medical centres AED</i>	<i>Pharmacies AED</i>	<i>Others AED</i>	<i>Total segments AED</i>	<i>Adjustments and eliminations AED</i>	<i>Consolidation AED</i>
<b>Revenue</b>							
Out patient revenue	1,873,958,303	318,403,216	-	-	2,192,361,519	(127,180,200)	2,065,181,319
In patient revenue	<u>1,136,375,042</u>	-	-	-	<u>1,136,375,042</u>	-	<u>1,136,375,042</u>
Total clinical revenue	3,010,333,345	318,403,216	-	-	3,328,736,561	(127,180,200)	3,201,556,361
Pharmacy sales	-	-	45,229,232	-	45,229,232	(1,111,305)	44,117,927
Others	54,441,873	3,370,837	2,495,471	760,780,935	821,089,116	(754,400,495)	66,688,621
Rental income	<u>4,846,932</u>	<u>29,710</u>	-	-	<u>4,876,642</u>	-	<u>4,876,642</u>
<b>Total revenue</b>	<u>3,069,622,150</u>	<u>321,803,763</u>	<u>47,724,703</u>	<u>760,780,935</u>	<u>4,199,931,551</u>	<u>(882,692,000)</u>	<u>3,317,239,551</u>
<b>Revenue</b>							
External customers	2,945,486,648	318,309,065	46,613,398	6,830,440	3,317,239,551	-	3,317,239,551
Intersegment	<u>124,135,502</u>	<u>3,494,698</u>	<u>1,111,305</u>	<u>753,950,495</u>	<u>882,692,000</u>	<u>(882,692,000)</u>	-
<b>Total revenue</b>	<u>3,069,622,150</u>	<u>321,803,763</u>	<u>47,724,703</u>	<u>760,780,935</u>	<u>4,199,931,551</u>	<u>(882,692,000)</u>	<u>3,317,239,551</u>
<b>Segment profit before tax</b>	328,795,975	66,013,368	3,909,532	(36,945,551)	361,773,324	-	361,773,324
Finance costs	<u>102,189,388</u>	<u>1,928,437</u>	-	<u>12,581</u>	<u>104,130,406</u>	-	<u>104,130,406</u>
<b>Profit before interest, taxation (EBIT)</b>	430,985,363	67,941,805	3,909,532	(36,932,970)	465,903,730	-	465,903,730
Depreciation and amortisation	<u>234,856,773</u>	<u>24,110,031</u>	<u>534,595</u>	<u>1,889,014</u>	<u>261,390,413</u>	-	<u>261,390,413</u>
<b>Profit before interest, taxation, depreciation, amortisation (EBITDA)</b>	<u>665,842,136</u>	<u>92,051,836</u>	<u>4,444,127</u>	<u>(35,043,956)</u>	<u>727,294,143</u>	-	<u>727,294,143</u>
Total assets as at 31 December 2023	<u>8,113,413,285</u>	<u>705,216,586</u>	<u>132,893,164</u>	<u>2,554,299,800</u>	<u>11,505,822,835</u>	<u>(6,364,417,783)</u>	<u>5,141,405,052</u>
Total liabilities as at 31 December 2023	<u>7,024,115,250</u>	<u>616,748,356</u>	<u>131,699,426</u>	<u>2,226,857,476</u>	<u>9,999,420,508</u>	<u>(6,415,072,388)</u>	<u>3,584,348,120</u>
Other disclosures:							
Additions to property and equipment	79,106,754	9,432,099	607,883	2,948,559	92,095,295	-	92,095,295
Additions to intangibles	4,054,016	479,879	-	322,195	4,856,090	-	4,856,090
Additions to capital work in progress	124,338	4,421,250	-	1,646,835	6,192,423	-	6,192,423

# Burjeel Holdings PLC

## NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 September 2024 (Unaudited)

### 18 SEGMENTAL REPORTING continued

For the three months period 30 September 2024

	<i>Hospitals centres AED</i>	<i>Medical centres AED</i>	<i>Pharmacies AED</i>	<i>Others AED</i>	<i>Total segments AED</i>	<i>Adjustments and eliminations AED</i>	<i>Consolidation AED</i>
<b>Revenue</b>							
Out patient revenue	781,346,154	95,982,650	-	-	877,328,804	(48,096,944)	829,231,860
In patient revenue	<u>442,062,294</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>442,062,294</u>	<u>-</u>	<u>442,062,294</u>
Total clinical revenue	1,223,408,448	95,982,650	-	-	1,319,391,098	(48,096,944)	1,271,294,154
Pharmacy sales	-	-	15,506,452	-	15,506,452	(31,273)	15,475,179
Others	15,032,511	1,420,536	252,500	337,955,912	354,661,459	(324,649,877)	30,011,582
Rental income	<u>1,805,128</u>	<u>(19,386)</u>	<u>-</u>	<u>-</u>	<u>1,785,742</u>	<u>-</u>	<u>1,785,742</u>
<b>Total revenue</b>	<u>1,240,246,087</u>	<u>97,383,800</u>	<u>15,758,952</u>	<u>337,955,912</u>	<u>1,691,344,751</u>	<u>(372,778,094)</u>	<u>1,318,566,657</u>
<b>Revenue</b>							
External customers	1,191,796,972	96,069,818	15,727,679	14,972,188	1,318,566,657	-	1,318,566,657
Intersegment	<u>48,449,115</u>	<u>1,313,982</u>	<u>31,273</u>	<u>322,983,724</u>	<u>372,778,094</u>	<u>(372,778,094)</u>	<u>-</u>
<b>Total revenue</b>	<u>1,240,246,087</u>	<u>97,383,800</u>	<u>15,758,952</u>	<u>337,955,912</u>	<u>1,691,344,751</u>	<u>(372,778,094)</u>	<u>1,318,566,657</u>
<b>Segment profit before tax</b>	158,590,919	10,719,901	332,369	(19,098,408)	150,544,781	-	150,544,781
Finance costs	<u>29,603,357</u>	<u>426,857</u>	<u>-</u>	<u>5,162,704</u>	<u>35,192,918</u>	<u>-</u>	<u>35,192,918</u>
<b>Profit before interest, taxation (EBIT)</b>	188,194,276	11,146,758	332,369	(13,935,704)	185,737,699	-	185,737,699
Depreciation and amortisation	<u>79,415,694</u>	<u>7,330,617</u>	<u>190,330</u>	<u>806,557</u>	<u>87,743,198</u>	<u>-</u>	<u>87,743,198</u>
<b>Profit before interest, taxation, depreciation, amortisation (EBITDA)</b>	<u>267,609,970</u>	<u>18,477,375</u>	<u>522,699</u>	<u>(13,129,147)</u>	<u>273,480,897</u>	<u>-</u>	<u>273,480,897</u>



# Burjeel Holdings PLC

## NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 September 2024 (Unaudited)

### 18 SEGMENTAL REPORTING continued

#### For the three months period 30 September 2023

	<i>Hospitals AED</i>	<i>Medical centres AED</i>	<i>Pharmacies AED</i>	<i>Others AED</i>	<i>Total segments AED</i>	<i>Adjustments and eliminations AED</i>	<i>Consolidation AED</i>
<b>Revenue</b>							
Out patient revenue	652,196,773	111,129,847	-	-	763,326,620	(37,017,763)	726,308,857
In patient revenue	<u>390,978,190</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>390,978,190</u>	<u>-</u>	<u>390,978,190</u>
Total clinical revenue	1,043,174,963	111,129,847	-	-	1,154,304,810	(37,017,763)	1,117,287,047
Pharmacy sales	-	-	13,242,398	-	13,242,398	(83,197)	13,159,201
Others	19,413,420	1,510,847	147,793	269,133,921	290,205,981	(266,582,690)	23,623,291
Rental income	<u>1,328,433</u>	<u>11,724</u>	<u>-</u>	<u>-</u>	<u>1,340,157</u>	<u>-</u>	<u>1,340,157</u>
<b>Total revenue</b>	<u><u>1,063,916,816</u></u>	<u><u>112,652,418</u></u>	<u><u>13,390,191</u></u>	<u><u>269,133,921</u></u>	<u><u>1,459,093,346</u></u>	<u><u>(303,683,650)</u></u>	<u><u>1,155,409,696</u></u>
<b>Revenue</b>							
External customers	1,028,047,191	111,354,280	13,306,994	2,701,231	1,155,409,696	-	1,155,409,696
Intersegment	<u>35,869,625</u>	<u>1,298,138</u>	<u>83,197</u>	<u>266,432,690</u>	<u>303,683,650</u>	<u>(303,683,650)</u>	<u>-</u>
<b>Total revenue</b>	<u><u>1,063,916,816</u></u>	<u><u>112,652,418</u></u>	<u><u>13,390,191</u></u>	<u><u>269,133,921</u></u>	<u><u>1,459,093,346</u></u>	<u><u>(303,683,650)</u></u>	<u><u>1,155,409,696</u></u>
<b>Segment profit before tax</b>	125,248,374	24,732,135	(279,256)	(12,641,863)	137,059,390	-	137,059,390
Finance costs	<u>32,833,006</u>	<u>732,769</u>	<u>-</u>	<u>4,115</u>	<u>33,569,890</u>	<u>-</u>	<u>33,569,890</u>
<b>Profit before interest, taxation (EBIT)</b>	158,081,380	25,464,904	(279,256)	(12,637,748)	170,629,280	-	170,629,280
Depreciation and amortisation	<u>80,288,150</u>	<u>8,511,676</u>	<u>175,523</u>	<u>718,215</u>	<u>89,693,564</u>	<u>-</u>	<u>89,693,564</u>
<b>Profit before interest, taxation, depreciation, amortisation (EBITDA)</b>	<u><u>238,369,530</u></u>	<u><u>33,976,580</u></u>	<u><u>(103,733)</u></u>	<u><u>(11,919,533)</u></u>	<u><u>260,322,844</u></u>	<u><u>-</u></u>	<u><u>260,322,844</u></u>

# Burjeel Holdings PLC

## NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 30 September 2024 (Unaudited)

### 18 SEGMENTAL REPORTING continued

Inter-segment revenues are eliminated upon consolidation and reflected in the 'adjustments and eliminations' column.

#### Revenue by Geographic segments:

	<i>Emirate of Abu Dhabi AED</i>	<i>Northern Emirates AED</i>	<i>Sultanate of Oman AED</i>	<i>Kingdom of Saudi Arabia AED</i>	<i>Total AED</i>
<b>For the nine months period ended 30 September 2024</b>					
Out patient revenue	2,054,883,769	143,715,258	103,951,226	2,946,018	2,305,496,271
In patient revenue	1,052,210,097	180,255,490	37,001,931	-	1,269,467,518
Pharmacy	46,044,810	-	-	-	46,044,810
Other income	<u>62,160,478</u>	<u>5,891,624</u>	<u>11,333,797</u>	<u>457,897</u>	<u>79,843,796</u>
	3,215,299,154	329,862,372	152,286,954	3,403,915	3,700,852,395
Rental income	<u>4,214,047</u>	<u>-</u>	<u>83,714</u>	<u>-</u>	<u>4,297,761</u>
Total revenue	<u>3,219,513,201</u>	<u>329,862,372</u>	<u>152,370,668</u>	<u>3,403,915</u>	<u>3,705,150,156</u>
<b>For the nine months period ended 30 September 2023</b>					
Out patient revenue	1,851,103,174	125,252,418	88,825,727	-	2,065,181,319
In patient revenue	966,972,653	136,331,882	33,070,507	-	1,136,375,042
Pharmacy	44,117,927	-	-	-	44,117,927
Other income	<u>49,255,766</u>	<u>7,940,168</u>	<u>9,492,687</u>	<u>-</u>	<u>66,688,621</u>
	2,911,449,520	269,524,468	131,388,921	-	3,312,362,909
Rental income	<u>4,792,928</u>	<u>-</u>	<u>83,714</u>	<u>-</u>	<u>4,876,642</u>
Total revenue	<u>2,916,242,448</u>	<u>269,524,468</u>	<u>131,472,635</u>	<u>-</u>	<u>3,317,239,551</u>
<b>For the three months period ended 30 September 2024</b>					
Out patient revenue	739,214,618	50,499,430	38,018,653	1,499,159	829,231,860
In patient revenue	363,185,781	65,060,017	13,816,496	-	442,062,294
Pharmacy	15,475,179	-	-	-	15,475,179
Other income	<u>22,484,382</u>	<u>2,840,128</u>	<u>4,416,659</u>	<u>270,413</u>	<u>30,011,582</u>
	1,140,359,960	118,399,575	56,251,808	1,769,572	1,316,780,915
Rental income	<u>1,750,682</u>	<u>-</u>	<u>35,060</u>	<u>-</u>	<u>1,785,742</u>
Total revenue	<u>1,142,110,642</u>	<u>118,399,575</u>	<u>56,286,868</u>	<u>1,769,572</u>	<u>1,318,566,657</u>
<b>For the three months period ended 30 September 2023</b>					
Out patient revenue	650,343,425	42,985,805	32,979,627	-	726,308,857
In patient revenue	327,042,521	52,070,654	11,865,015	-	390,978,190
Pharmacy	13,159,201	-	-	-	13,159,201
Other income	<u>16,014,317</u>	<u>4,254,812</u>	<u>3,354,162</u>	<u>-</u>	<u>23,623,291</u>
	1,006,559,464	99,311,271	48,198,804	-	1,154,069,539
Rental income	<u>1,312,252</u>	<u>-</u>	<u>27,905</u>	<u>-</u>	<u>1,340,157</u>
Total revenue	<u>1,007,871,716</u>	<u>99,311,271</u>	<u>48,226,709</u>	<u>-</u>	<u>1,155,409,696</u>